| First Author | Nelson CA | Year | 2011 |
| Journal | Am J Pathol | Volume | 178 |
| Issue | 6 | Pages | 2611-21 |
| PubMed ID | 21641384 | Mgi Jnum | J:173295 |
| Mgi Id | MGI:5013836 | Doi | 10.1016/j.ajpath.2011.02.024 |
| Citation | Nelson CA, et al. (2011) Inhibiting TGF-beta Activity Improves Respiratory Function in mdx Mice. Am J Pathol 178(6):2611-21 |
| abstractText | Respiratory function is the main cause of mortality in patients with Duchenne muscular dystrophy (DMD). Elevated levels of TGF-beta play a key role in the pathophysiology of DMD. To determine whether therapeutic attenuation of TGF-beta signaling improves respiratory function, mdx mice were treated from 2 weeks of age to 2 months or 9 months of age with either 1D11 (a neutralizing antibody to all three isoforms of TGF-beta), losartan (an angiotensin receptor antagonist), or a combination of the two agents. Respiratory function was measured in nonanesthetized mice by plethysmography. The 9-month-old mdx mice had elevated Penh values and decreased breathing frequency, due primarily to decreased inspiratory flow rate. All treatments normalized Penh values and increased peak inspiratory flow, leading to decreased inspiration times and breathing frequency. Additionally, forelimb grip strength was improved after 1D11 treatment at both 2 and 9 months of age, whereas, losartan improved grip strength only at 2 months. Decreased serum creatine kinase levels (significant improvement for all groups), increased diaphragm muscle fiber density, and decreased hydroxyproline levels (significant improvement for 1D11 only) also suggested improved muscle function after treatment. For all endpoints, 1D11 was equivalent or superior to losartan; coadministration of the two agents was not superior to 1D11 alone. In conclusion, TGF-beta antagonism may be a useful therapeutic approach for treating DMD patients. |
